Cancer Diagnostics Market: Rising Global Cancer Incidence, Screening Programmes, Liquid Biopsy and Precision Oncology, and AI-Enabled Imaging and Pathology to Drive Strong Market Expansion Through 2036

The global Cancer Diagnostics Market was valued at USD 30,424.8 million in 2025 and is projected to expand at a strong CAGR of 7.9% to reach approximately USD 65,079.2 million by 2036, driven by a rising global cancer burden, with the WHO’s International Agency for Research on Cancer projecting more than 35 million new cases in 2050, up 77% from 2022, expanding screening programmes, the shift toward precision oncology that requires genomic testing, and adoption of liquid biopsy, digital pathology, and AI-assisted imaging. The market encompasses cancer diagnostics by product, technology, test type, cancer type, application, and end user.

The Cancer Diagnostics Market’s strong 7.9% CAGR reflects growing need for earlier and more precise cancer detection. IARC estimates that there were about 20 million new cancer cases and 9.7 million cancer deaths in 2022, with lung, female breast, colorectal, prostate, and stomach cancers the most common. Ageing populations, lifestyle factors, and better detection are increasing case numbers, while new therapies that target specific mutations require more testing for each patient. Spending is shifting toward molecular testing and digital tools, which offer higher value per test and support personalized treatment decisions.

Executive Snapshot

What does cancer diagnostics include?
Cancer diagnostics covers imaging such as CT, MRI, PET, mammography, and ultrasound; tissue biopsy and pathology; laboratory tests including tumor markers and immunohistochemistry; molecular and genomic tests such as PCR and next-generation sequencing; and liquid biopsy tests that analyse tumor DNA in blood. These tools are used for screening, diagnosis, staging, treatment selection, and monitoring. Diagnostics account for a relatively small share of cancer care costs but strongly influence treatment decisions. It spans imaging, tissue biopsy, laboratory tests, molecular assays, and digital pathology.

How large is the global cancer burden?
IARC estimates about 20 million new cancer cases in 2022, with lung cancer accounting for 12.4% of cases and 18.7% of deaths. New cases are projected to exceed 35 million by 2050, with the largest relative increases in low and medium Human Development Index countries. This growth will increase demand for diagnostic capacity worldwide. Breast cancer is the most common cancer among women and lung cancer the leading cause of cancer death.

Why is screening important?
Screening finds cancers at earlier stages, when treatment is more effective and less costly. Established programmes include mammography for breast cancer, colonoscopy and stool tests for colorectal cancer, cervical cytology and HPV testing, and low-dose CT for lung cancer in high-risk groups. Expanding eligibility and new tests increase screening volumes. Lung cancer screening with low-dose CT is being introduced in more countries.

What is precision oncology?
Many cancer therapies target specific genetic mutations or biomarkers, such as EGFR, ALK, HER2, BRCA, and PD-L1. Companion diagnostic tests identify which patients are likely to benefit. Next-generation sequencing panels test many genes at once, and guidelines increasingly recommend broad genomic profiling for advanced cancers. Testing rates for key biomarkers still vary widely between hospitals and countries. Biomarker testing identifies patients who are likely to benefit from targeted therapies.

How is liquid biopsy changing diagnostics?
Liquid biopsy detects tumor DNA, RNA, or cells in blood, allowing less invasive testing. It is used to identify mutations when tissue is insufficient, monitor treatment response, and detect minimal residual disease after surgery. Multi-cancer early detection tests are being studied for screening. Adoption depends on clinical evidence and reimbursement. Minimal residual disease testing helps doctors decide whether more treatment is needed after surgery. Blood-based tests can detect tumor DNA and monitor response to treatment.

What role does AI play?
AI tools help radiologists detect suspicious lesions on mammograms, CT scans, and other images, and help pathologists analyse digital slides. They can improve accuracy, reduce workload, and prioritize urgent cases. Regulatory approvals for AI-based diagnostic tools are increasing. Digital pathology also allows remote review and second opinions. AI tools help radiologists and pathologists read images faster and more consistently.

Which cancer types drive testing?
Breast, lung, colorectal, and prostate cancers account for the largest testing volumes because of their high incidence and established screening. Blood cancers rely heavily on flow cytometry and molecular testing. Rare cancers increasingly use genomic profiling. Hematology diagnostics use flow cytometry and molecular tests to classify blood cancers.

Who uses cancer diagnostics?
Hospitals, independent laboratories, diagnostic imaging centers, cancer research institutes, and physician offices are the main users. Reference laboratories perform complex molecular tests, while hospitals provide imaging and pathology. Pharmaceutical companies use diagnostics in clinical trials. Centralized laboratories handle complex genomic tests, while hospitals focus on routine work.

What challenges face the market?
Reimbursement for new tests, especially multi-cancer screening, is uncertain. Shortages of pathologists and radiologists limit capacity. Access to advanced diagnostics is limited in many low- and middle-income countries. Workforce shortages are especially severe in pathology.

Which cancer diagnostics market segments are growing fastest?
Liquid biopsy; next-generation sequencing; companion diagnostics; AI-enabled imaging and digital pathology; and lung and colorectal cancer screening are the fastest-growing segments. Colorectal screening with stool DNA tests has grown quickly in the United States.

Market Dynamics: Cancer Diagnostics Market

  • Imaging remaining the largest segment: Imaging is used throughout cancer care. Equipment upgrades and procedure growth support demand.
  • Molecular testing growing fastest: Genomic testing is essential for targeted therapies. Test volumes are rising quickly.
  • Screening expansion: Programmes are widening eligibility and adding new tests. Earlier detection improves outcomes.
  • Liquid biopsy adoption: Blood-based tests are used for profiling and monitoring. Evidence and reimbursement are expanding.
  • AI adoption: AI supports imaging and pathology. Regulators are approving more AI tools.
  • Rising global burden: IARC projects 35 million new cases by 2050. Capacity must grow in all regions.
  • Point-of-care and decentralized testing: Simpler tests bring diagnosis closer to patients. This helps in low-resource settings.
  • Data integration: Combining imaging, pathology, and genomic data improves decisions. Software platforms support this integration.
  • Companion diagnostics: Each new targeted therapy approval often comes with a companion test, linking diagnostic demand directly to drug development pipelines. This creates long-term partnerships between pharmaceutical and diagnostic companies.

Market Segmentation: Cancer Diagnostics Market

By Product
  • Instruments
    • Molecular Diagnostic Instruments
      • PCR Systems
      • NGS Systems
      • Microarray Systems
      • ISH Systems
    • Immunodiagnostic Instruments
      • Immunoassay Analyzers
      • IHC Staining Systems
    • Flow Cytometry Systems
    • Anatomic Pathology Instruments
      • Tissue Processing Systems
      • Slide Staining Systems
      • Microtomes
      • Embedding Systems
      • Cytology Cell Processors
      • Digital Pathology Scanners
    • Imaging Systems
      • CT Systems
      • MRI Systems
      • PET / PET-CT Systems
      • Mammography Systems
      • Ultrasound Systems
  • Consumables
    • Kits & Reagents
    • Antibodies
    • Probes
    • Assay Panels
    • Sample Preparation Reagents
    • Contrast Agents
    • Radiopharmaceuticals
    • Other Consumables
  • Software & Services
    • Diagnostic Analysis Software
    • Digital Pathology Software
    • AI-Based Diagnostic Software
    • Laboratory Information Management Software
    • Testing & Laboratory Services
    • Maintenance & Technical Support Services
By Cancer Type
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Cervical Cancer
  • Gastric Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • Head & Neck Cancer
  • Kidney Cancer
  • Bladder Cancer
  • Skin Cancer / Melanoma
  • Thyroid Cancer
  • Other Solid Tumors
By Technology
  • Molecular Diagnostics
    • Polymerase Chain Reaction (PCR)
    • Real-Time PCR (qPCR)
    • Digital PCR (dPCR)
    • Next-Generation Sequencing (NGS)
    • In Situ Hybridization (ISH)
      • Fluorescence In Situ Hybridization (FISH)
      • Chromogenic In Situ Hybridization (CISH)
    • Microarray
    • Other Molecular Diagnostic Technologies
  • Immunodiagnostics
    • Immunohistochemistry (IHC)
    • Immunoassays
    • Enzyme-Linked Immunosorbent Assay (ELISA)
    • Chemiluminescence Immunoassay (CLIA)
    • Other Immunodiagnostic Technologies
  • Flow Cytometry
    • Conventional Flow Cytometry
    • Multiparameter Flow Cytometry
  • Imaging Technologies
    • Magnetic Resonance Imaging (MRI)
    • Computed Tomography (CT)
    • Positron Emission Tomography (PET)
    • PET-CT / PET-MRI
    • Mammography
    • Ultrasound
    • Other Imaging Technologies
  • Anatomic Pathology
    • Histopathology
    • Cytopathology
    • Digital Pathology
    • Other Pathology Technologies
  • Other Emerging Technologies
By Form
  • Tissue-Based Samples
    • Tumor Biopsy Samples
    • Surgical Resection Samples
    • Fine Needle Aspiration Samples
  • Blood-Based Samples
    • Whole Blood
    • Plasma
    • Serum
  • Other Liquid Biopsy Samples
    • Urine
    • Cerebrospinal Fluid (CSF)
    • Pleural Fluid
    • Saliva
  • Other Biological Samples
By End Use Industries
  • Hospitals & Clinics
    • Multi-Specialty Hospitals
    • Oncology Hospitals
    • Specialty Cancer Clinics
    • Outpatient Oncology Centers
  • Diagnostic Laboratories
    • Hospital-Based Laboratories
    • Independent Diagnostic Laboratories
    • Reference Laboratories
    • Molecular Diagnostic Laboratories
  • Academic & Research Institutes
    • Cancer Research Institutes
    • University Hospitals
    • Academic Medical Centers
  • Pharmaceutical & Biotechnology Companies
    • Pharmaceutical Manufacturers
    • Biotechnology Companies
    • Contract Research Organizations (CROs)
  • Other End Users
By Application
  • Screening & Early Detection
  • Diagnosis & Disease Characterization
  • Treatment Selection & Decision Support
  • Treatment Monitoring & Response Assessment
  • Disease Progression & Recurrence Monitoring
  • Post-Treatment Surveillance
By Geography
  • North America: United States, Canada, and Mexico
  • Europe:  Germany, U.K., France, Italy, Spain, Russia, Benelux, Nordics, and Rest of Europe
  • Asia Pacific: China, Japan, India, South Korea, Australia, New Zealand, Taiwan, South East Asia, and Rest of Asia Pacific
  • Latin America: Brazil, Argentina, Columbia, Chile, Peru, and Rest of Latin America
  • Middle East: Saudi Arabia, United Arab Emirates, Oman, Qatar, and Rest of Middle East
  • Africa: Nigeria, Egypt, Ethiopia, South Africa, and Rest of Africa

Key Growth Drivers: Cancer Diagnostics Market

  1. Ageing populations: Cancer risk rises with age. Most cancers are diagnosed in people over 60.
  2. Precision medicine: Targeted therapies require biomarker testing. Each new targeted drug often requires a companion test.
  3. Screening programmes: Governments and insurers fund early detection. Screening reduces deaths from several common cancers.
  4. Technology advances: Sequencing and imaging improvements expand capabilities. Sequencing costs have fallen substantially.
  5. Rising cancer incidence: About 20 million new cases were diagnosed in 2022. Lung, breast, and colorectal cancers lead incidence.
  6. Investment in healthcare infrastructure: Emerging markets expand diagnostic capacity. Governments in Asia and Africa are adding cancer centers.
  7. Reimbursement expansion: Insurers are covering more molecular and screening tests. Coverage decisions unlock demand.
  8. Pharmaceutical partnerships: Drug developers partner with diagnostic companies. Companion diagnostics are co-developed with drugs.

Regional Outlook: Cancer Diagnostics Market

  • North America: The United States is the largest market, with high use of imaging, genomic testing, and liquid biopsy, and broad screening programmes. Reimbursement decisions strongly influence adoption of new tests. Large reference laboratories perform much of the molecular testing.
  • Europe: Europe has organized screening programmes for breast, colorectal, and cervical cancer, and is expanding lung screening. Genomic testing is growing under national precision medicine initiatives. EU cancer plans support screening expansion.
  • Asia-Pacific: China, Japan, India, South Korea, and Australia are major markets. China and India face large and growing cancer burdens, and are investing in screening, imaging, and molecular testing. Japan and South Korea have advanced gastric and colorectal screening programmes.
  • Middle East & Africa: Gulf countries are investing in cancer centers and screening. Africa faces a fast-growing cancer burden, and IARC projects the largest relative increases in lower-income countries, where diagnostic capacity is limited. IARC projects cancer cases in Africa will rise sharply by 2050.

Competitive Landscape: Cancer Diagnostics Market

Consultant POV

The Cancer Diagnostics Market’s strong 7.9% CAGR from USD 30,424.8 million in 2025 toward approximately USD 65,079.2 million by 2036 is anchored in the rising cancer burden, expanding screening, precision oncology, and new technologies. Companies such as Roche Diagnostics, Illumina, and Siemens Healthineers are investing in molecular, imaging, and AI tools. Over the forecast period, liquid biopsy, genomic testing, and AI will drive strong growth. Expanding capacity in low- and middle-income countries will be essential as the global cancer burden grows. Diagnostic companies that combine molecular, imaging, and digital capabilities will be best placed.

About Constancy Researchers Private Limited

Constancy Researchers is a global market intelligence and strategic advisory firm helping organizations navigate complex markets and make high-impact decisions with confidence. In an environment defined by rapid technological change, shifting demand patterns, and evolving competitive dynamics, we provide clarity where it matters most—at the point of decision-making. By combining deep industry understanding, rigorous analytics, and structured thinking, we enable leadership teams to identify opportunities, mitigate risks, and build strategies that drive sustainable growth.

Speak with an Analyst

    Download TOC